市場調查報告書
商品編碼
1298660
藥物警戒和藥物安全軟體市場:2023-2028年全球行業趨勢、佔有率、規模、成長、機會及預測Pharmacovigilance and Drug Safety Software Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
全球藥物警戒和藥物安全軟體市場規模在2022年達到1.899億美元。展望未來,IMARC Group預計到2028年,該市場規模將達到2.833億美元,2023-2028年期間的年復合成長率(CAGR)為6.51%。
藥物警戒和藥品安全軟體用於檢測、評估、了解和預防與藥品、醫療器械和醫藥產品相關的不良反應。全球的醫療保健公司都在使用該軟體,以確保全球監管合規性,更快地做出科學的安全決策,整合安全和風險管理,並降低藥物警戒的成本。如今,服務提供商正在提供靈活、創新和可擴展的變體,以滿足醫療保健公司獨特的業務和產品安全要求。
藥物警戒和藥物安全監測是醫藥產品開發商、許可證持有者和臨床研究者的強制性要求。然而,藥物警戒和藥物安全監測是一個時間密集、成本高昂的過程,這也是促使採用藥物警戒和藥物安全軟體來維護安全數據、降低成本並提供最佳監測和報告工作流程的關鍵因素之一。此外,許多國家的衛生機構正在實施嚴格的公共衛生法律,這也鼓勵製藥和生物技術公司採用高效的藥物警戒和藥物安全軟體。此外,由於藥物不良反應(ADR)發生率的上升,全球對安全藥物和藥品的需求也在不斷攀升,這也促進了市場的成長。除此之外,由於臨床試驗的快速數位化,藥物警戒和藥物安全軟體的採用率也在上升,以確保在不破壞傳統訊號檢測、驗證和管理工作流程的情況下實施新方法。此外,知名廠商正在實施自動化,採用先進技術,並利用分析結果提高藥物警戒和藥物安全軟體的合規性和產品安全性。預計這將為市場帶來積極的前景。
The global pharmacovigilance and drug safety software market size reached US$ 189.9 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 283.3 Million by 2028, exhibiting a growth rate (CAGR) of 6.51% during 2023-2028.
Pharmacovigilance and drug safety software is used to detect, assess, understand, and prevent adverse effects related to medicines, medical devices, and pharmaceutical products. It is utilized by health firms worldwide to ensure global regulatory compliance, make faster science-based safety decisions, integrate safety and risk management, and lower the cost of pharmacovigilance. Nowadays, service providers are offering flexible, innovative, and scalable variants to meet the unique business and product safety requirements of health firms.
Pharmacovigilance and drug safety monitoring are mandatory requirements for medicinal product developers, license holders, and clinical investigators. However, they can be time-intensive and costly processes, which represents one of the key factors catalyzing the adoption of pharmacovigilance and drug safety software to maintain safety data, minimize costs, and deliver best-practice monitoring and reporting workflows. In addition to this, health agencies of numerous countries are implementing stringent laws regarding public health, which is encouraging pharmaceutical and biotechnology companies to adopt efficient software for pharmacovigilance and drug safety. Moreover, the escalating demand for safe drugs and medicines around the world on account of the increasing incidences of adverse drug reaction (ADR) is contributing to the market growth. Apart from this, due to the rapid digitization of clinical trials, there is a rise in the adoption of pharmacovigilance and drug safety software to ensure the implementation of novel methods without disrupting traditional signal detection, validation, and management workflow. Furthermore, prominent vendors are implementing automation, adopting advanced technologies, and leveraging insights from analytics that improve compliance and product safety in pharmacovigilance and drug safety software. This is anticipated to provide a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmacovigilance and drug safety software market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on functionality, delivery mode and end user.
Adverse Event Reporting Software
Drug Safety Audits Software
Issue Tracking Software
Fully Integrated Software
On-premises
Cloud-based
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Business Process Outsourcing Firms
Others
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Ab Cube, Anju Software Inc., ArisGlobal LLC, Cognizant, Ennov Solutions Inc., Extedo GmbH, Max Application, Oracle Corporation, Sarjen Systems Pvt Ltd, Sparta Systems Inc. (Honeywell International Inc.), Tata Consultancy Services Limited, United BioSource LLC and Wipro Limited.
Key Questions Answered in This Report
1. What was the size of the global pharmacovigilance and drug safety software market in 2022?
2. What is the expected growth rate of the global pharmacovigilance and drug safety software market during 2023-2028?
3. What has been the impact of COVID-19 on the global pharmacovigilance and drug safety software market?
4. What are the key factors driving the global pharmacovigilance and drug safety software market?
5. What is the breakup of the global pharmacovigilance and drug safety software market based on the functionality?
6. What is the breakup of the global pharmacovigilance and drug safety software market based on the delivery mode?
7. What is the breakup of the global pharmacovigilance and drug safety software market based on the end user?
8. What are the key regions in the global pharmacovigilance and drug safety software market?
9. Who are the key players/companies in the global pharmacovigilance and drug safety software market?